X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1057) 1057
Publication (132) 132
Patent (23) 23
Book / eBook (13) 13
Book Chapter (10) 10
Book Review (10) 10
Web Resource (8) 8
Conference Proceeding (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (607) 607
oncology (411) 411
index medicus (362) 362
female (359) 359
male (328) 328
middle aged (321) 321
adult (266) 266
aged (260) 260
cancer (206) 206
treatment outcome (143) 143
neoplasms - drug therapy (134) 134
antineoplastic agents - therapeutic use (124) 124
aged, 80 and over (111) 111
mutation (103) 103
article (101) 101
tumors (90) 90
antineoplastic combined chemotherapy protocols - therapeutic use (83) 83
therapy (81) 81
research (80) 80
chemotherapy (75) 75
care and treatment (74) 74
neoplasms - pathology (70) 70
neoplasms - genetics (68) 68
hematology (67) 67
young adult (67) 67
prognosis (65) 65
solid tumors (65) 65
clinical trials (64) 64
molecular targeted therapy (63) 63
adolescent (57) 57
antineoplastic agents - adverse effects (56) 56
expression (56) 56
dose-response relationship, drug (55) 55
animals (53) 53
antineoplastic combined chemotherapy protocols - adverse effects (53) 53
maximum tolerated dose (53) 53
disease-free survival (49) 49
survival (49) 49
bevacizumab (48) 48
patients (48) 48
breast-cancer (47) 47
cell lung-cancer (47) 47
retrospective studies (47) 47
mutations (44) 44
targeted therapy (44) 44
antineoplastic agents - administration & dosage (43) 43
medicine & public health (43) 43
neoplasms - metabolism (43) 43
drug therapy (42) 42
immunotherapy (41) 41
metastasis (41) 41
neoplasm staging (41) 41
protein kinase inhibitors - therapeutic use (41) 41
melanoma (40) 40
neoplasms (39) 39
pharmacology & pharmacy (38) 38
drug administration schedule (37) 37
analysis (35) 35
leukemia (35) 35
precision medicine (35) 35
antineoplastic agents (34) 34
antineoplastic agents - pharmacology (34) 34
genetic aspects (34) 34
abridged index medicus (33) 33
carcinoma (33) 33
clinical trials, phase i as topic (33) 33
medicine, general & internal (33) 33
angiogenesis (32) 32
pharmacology/toxicology (32) 32
phase-i (32) 32
survival rate (32) 32
clinical trials as topic (31) 31
colorectal-cancer (31) 31
neoplasms - therapy (31) 31
apoptosis (29) 29
resistance (29) 29
time factors (29) 29
antineoplastic combined chemotherapy protocols - administration & dosage (28) 28
health aspects (28) 28
medicine (28) 28
chronic myelogenous leukemia (27) 27
dermatology (27) 27
hematology, oncology and palliative medicine (27) 27
phase i (27) 27
phosphatidylinositol 3-kinases - genetics (27) 27
protein kinase inhibitors - administration & dosage (27) 27
biomarkers, tumor - genetics (26) 26
biopsy (26) 26
chronic myeloid-leukemia (26) 26
disease progression (26) 26
high-throughput nucleotide sequencing (26) 26
kaplan-meier estimate (26) 26
pathway (26) 26
cancer therapies (25) 25
child (25) 25
protein kinase inhibitors - adverse effects (25) 25
proto-oncogene proteins b-raf - genetics (25) 25
research paper (25) 25
survival analysis (25) 25
toxicity (25) 25
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncology (Williston Park, N.Y.), ISSN 0890-9091, 04/2018, Volume 32, Issue 4, pp. 150 - 163
In August 2017, Drs. Kurzrock and Kato and colleagues published a study[1] analyzing potential genetic biomarkers of so-called "hyperprogressors"-cancer... 
ONCOLOGY
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4242 - 4250
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2016, Volume 13, Issue 7, pp. 399 - 400
A patient's right to obtain medication that will be ineffective against his/her terminal illness and will cause his/her death should also encompass the right... 
ONCOLOGY | Medical policy | Analysis | Right to die
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors
Journal Article
Cancer, ISSN 0008-543X, 09/2001, Volume 92, Issue S6, pp. 1684 - 1688
Journal Article
Journal Article
Journal Article